Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model

References

• Chari RV. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc Chem Res 2008;41:98–107.
   PubMed Web of Science ®Google Scholar
• Senter PD. Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 2009;13:235–44.
   PubMed Web of Science ®Google Scholar
• Vaishampayan U, Glode M, Du W, Kraft A, Hudes G, Wright J, . Phase II study of dolastatin-10 in patients with hormone-refractory metastatic prostate adenocarcinoma. Clin Cancer Res 2000;6:4205–8.
   PubMed Web of Science ®Google Scholar
• Doronina SO, Mendelsohn BA, Bovee TD, Cervemy CG, Alley SC, Meyer DL, . Enhanced activity of monomethylauristatin F through monoclonal antibody delivery: Effects of linker technology on efficacy and toxicity. Bioconjug Chem 2006;17:114–24.
   PubMed Web of Science ®Google Scholar
• Younes A, Forero-Torres A, Bartlett NL, Leonard JP, Rege B, Kennedy DA, . Objective responses in a phase I dose-escalation study of SGN-35, a novel antibody-drug conjugate (ADC) targeting CD30, in patients with relapsed or refractory Hodgkin lymphoma. J Clin Oncol 2008;26(May 20 Suppl) ASCO Annual Meeting Abstract 8526.
   Google Scholar
• Hwu P, Sznol M, Kluger H, Rink L, Kim KB, Papadopoulos NE, . A phase I/II study of CR011-vcMMAE, an antibody toxin conjugate drug, in patients with unresectable stage III/IV melanoma. J Clin Oncol 2008;26(May 20 Suppl) ASCO Annual Meeting Abstract 9029.
   Google Scholar
• Martensson L, Nilsson R, Ohlsson T, Sjogren HO, Strand SE, Tennvall J. High-dose radioimmunotherapy combined with extracorporeal depletion in a syngeneic rat tumor model – evaluation of toxicity, therapeutic effect and tumor model. Cancer 2010;116(4 Suppl):1043–52.
   Google Scholar
• Martensson L, Wang Z, Nilsson R, Ohlsson T, Senter P, Sjogren HO, . Determining maximal tolerable dose of the monoclonal antibody BR96 labeled with 90Y or 177Lu in rats: Establishment of a syngeneic tumor model to evaluate means to improve radioimmunotherapy. Clin Cancer Res 2005;11(19 Pt 2):7104s–8s.
   Google Scholar
• Nilsson R, Martensson L, Eriksson SE, Sjogren HO, Tennvall J. Toxicity-reducing potential of ECAT in combination with the auristatin-conjugated mAb BR96 in a syngeneic rat tumor model. Cancer 2010;116(4 Suppl):1033–42.
   Google Scholar
• Sjogren HO, Isaksson M, Willner D, Hellstrom I, Hellstrom KE, Trail PA. Antitumor activity of carcinoma-reactive BR96-doxorubicin conjugate against human carcinomas in athymic mice and rats and syngeneic rat carcinomas in immunocompetent rats. Cancer Res 1997;57:4530–6.
   PubMed Web of Science ®Google Scholar
• Ross HJ, Hart LL, Swanson PM, Ratrick MU, Figlin RA, Jacobs AD, . A randomized, multicenter study to determine the safety and efficacy of the immunoconjugate SGN-15 plus docetaxel for the treatment of non-small cell lung carcinoma. Lung Cancer 2006;54:69–77.
   PubMed Web of Science ®Google Scholar
• Wilbur DS, Chyan MK, Hamlin DK, Kegley BB, Nilsson R, Sandberg BE, . Trifunctional conjugation reagents. Reagents that contain a biotin and a radiometal chelation moiety for application to extracorporeal affinity adsorption of radiolabeled antibodies. Bioconjug Chem 2002; 13:1079–92.
   PubMed Web of Science ®Google Scholar
• Wang Z, Martensson L, Nilsson R, Bendahl PO, Lindgren L, Ohlsson T, . Blood pharmacokinetics of various monoclonal antibodies labeled with a new trifunctional chelating reagent for simultaneous conjugation with 1,4,7,10-tetraazacyclododecane-N,N′,N″,N′″-tetraacetic acid and biotin before radiolabeling. Clin Cancer Res 2005;11(19 Pt 2): 7171s–7s.
   Google Scholar
• Pass D, Freeth G. The rat. ANZCCART 1993;6:1–4.
   Google Scholar
• Sun MM, Beam KS, Cerveny CG, Hamblett KJ, Blackmore RS, Torgov MY, . Reduction-alkylation strategies for the modification of specific monoclonal antibody disulfides. Bioconjug Chem 2005;16:1282–90.
   PubMed Web of Science ®Google Scholar
• Sharkey RM, Karacay H, Goldenberg DM. Improving the treatment of non-Hodgkin lymphoma with antibody-targeted radionuclides. Cancer 2010;116(4 Suppl): 1134–45.
   Google Scholar